IQVIA Holdings Inc. $IQV Shares Bought by Aster Capital Management DIFC Ltd

Aster Capital Management DIFC Ltd boosted its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 444.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 13,863 shares of the medical research company’s stock after purchasing an additional 11,318 shares during the period. IQVIA makes up approximately 1.4% of Aster Capital Management DIFC Ltd’s holdings, making the stock its 11th biggest position. Aster Capital Management DIFC Ltd’s holdings in IQVIA were worth $3,125,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in IQV. Ameliora Wealth Management Ltd. acquired a new stake in IQVIA during the fourth quarter valued at approximately $25,000. International Assets Investment Management LLC acquired a new stake in IQVIA during the fourth quarter valued at approximately $27,000. Gilpin Wealth Management LLC acquired a new stake in IQVIA during the fourth quarter valued at approximately $27,000. Measured Wealth Private Client Group LLC acquired a new stake in IQVIA during the third quarter valued at approximately $30,000. Finally, Activest Wealth Management lifted its stake in IQVIA by 590.0% during the fourth quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 118 shares during the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Stock Down 1.9%

IQV stock opened at $178.07 on Tuesday. IQVIA Holdings Inc. has a 12-month low of $153.01 and a 12-month high of $247.04. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. The company has a market cap of $29.72 billion, a price-to-earnings ratio of 22.07, a PEG ratio of 1.56 and a beta of 1.21. The company has a 50 day moving average of $173.65 and a two-hundred day moving average of $193.06.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The company had revenue of $4.15 billion during the quarter, compared to the consensus estimate of $4.10 billion. During the same quarter in the prior year, the firm earned $2.70 EPS. The company’s revenue was up 8.4% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, equities analysts anticipate that IQVIA Holdings Inc. will post 11.6 earnings per share for the current fiscal year.

IQVIA announced that its board has initiated a share repurchase program on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the medical research company to buy up to 6.8% of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s leadership believes its shares are undervalued.

Analyst Upgrades and Downgrades

Several analysts recently commented on IQV shares. Evercore reissued an “outperform” rating and set a $185.00 target price on shares of IQVIA in a research note on Wednesday, April 8th. Barclays raised shares of IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 target price for the company in a research note on Friday, March 6th. Weiss Ratings downgraded shares of IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research report on Monday, May 4th. HSBC set a $210.00 price target on shares of IQVIA in a research report on Wednesday, June 3rd. Finally, Wall Street Zen upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a research report on Sunday. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $224.13.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.